Rosuvastatin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heart Failure, Congestive

Conditions

Heart Failure, Congestive

Trial Timeline

Feb 1, 2003 → —

NCT ID

NCT00240292

About Rosuvastatin

Rosuvastatin is a phase 3 stage product being developed by AstraZeneca for Heart Failure, Congestive. The current trial status is completed. This product is registered under clinical trial identifier NCT00240292. Target conditions include Heart Failure, Congestive.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00160745	Phase 2	Completed	—	Sep 1, 2006	Hypercholesterolemia
NCT04846231	Phase 2	Completed	Apr 23, 2021	Jul 19, 2022	Hypercholesterolemia
NCT02561845	Pre-clinical	Withdrawn	Oct 1, 2015	Oct 1, 2015	PCI Patients
NCT02484027	Approved	UNKNOWN	Sep 1, 2015	Sep 1, 2018	Infarction, Anterior Cerebral Artery
NCT02077257	Approved	UNKNOWN	Mar 1, 2014	May 1, 2016	Acute Coronary Syndrome
NCT01837823	Phase 2	Completed	Jul 1, 2013	Apr 1, 2015	Obstructive Coronary Artery Disease
NCT01490398	Approved	Completed	Dec 1, 2011	Oct 1, 2013	Hypertension
NCT01364220	Phase 3	Terminated	Aug 1, 2010	Apr 1, 2013	Stroke
NCT00815659	Approved	Completed	Dec 1, 2008	Mar 1, 2010	Metabolic Syndrome
NCT00747149	Approved	Completed	May 1, 2008	Aug 1, 2009	Type 2 Diabetes
NCT00473655	Approved	Completed	Jan 1, 2007	Feb 1, 2009	Hypertriglyceridemia
NCT00335699	Approved	Completed	Aug 1, 2005	Jan 1, 2007	Hypercholesterolemia
NCT00184951	Phase 2	Completed	Apr 1, 2004	Jul 1, 2005	HIV Infections
NCT00240305	Phase 3	Completed	Apr 1, 2004	May 1, 2006	Metabolic Syndrome
NCT00176332	Phase 2	Completed	Mar 1, 2004	Dec 1, 2006	Heart Failure
NCT00228514	Phase 3	Completed	Feb 1, 2004	Jul 1, 2007	Rosuvastatin
NCT00240266	Phase 3	Completed	Aug 1, 2003	Dec 1, 2004	Metabolic Syndrome
NCT00241488	Phase 3	Completed	Jun 1, 2003	Feb 1, 2007	Hypercholesterolemia
NCT00660764	Pre-clinical	Completed	May 1, 2003	Apr 1, 2005	Hypercholesterolemia
NCT00239681	Phase 3	Terminated	Feb 1, 2003	Sep 1, 2008	Elevated High-sensitivity C-Reactive Protein (hsCRP)

Competing Products

20 competing products in Heart Failure, Congestive

See all competitors

Product	Company	Stage	Hype Score
IV diuretic	Nuwellis	Pre-clinical	15
IV Loop Diuretics	Nuwellis	Pre-clinical	15
Stepped pharmacologic care	Nuwellis	Phase 3	69
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	15
TRV120027 + Normal Saline	Trevena	Phase 1	25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	44
TRV120027 + Placebo	Trevena	Phase 1/2	33
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	44
INXN-4001	Precigen	Phase 1	28
LY3461767 + Placebo	Eli Lilly	Phase 1	33
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	85
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	52
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	85
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	77
Olmesartan	Daiichi Sankyo	Phase 3	77
Carperitide + Placebo	Daiichi Sankyo	Phase 2	52
Edoxaban	Daiichi Sankyo	Pre-clinical	23
Regadenoson	Astellas Pharma	Phase 1	33
Advagraf + Prograf	Astellas Pharma	Phase 2	52
FK506E	Astellas Pharma	Phase 3	77

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved